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Summary: Transcranial magnetic stimulation (TMS) has been applied to a growing
number of psychiatric disorders as a noninvasive probe to study the underlying
neurobiologic processes involved in psychiatric disorders and as a putative treatment.
Transcranial magnetic stimulation is unparalleled in its ability to test the hypotheses
generated by functional neuroimaging studies by modulating activity in selected neural
circuits. As a focal intervention that may in some cases exert lasting effects, TMS
offers the hope of targeting and ameliorating the circuitry underlying psychiatric
disorders. The ultimate success of such an approach depends on our knowledge of the
neural circuitry underlying these disorders, of how TMS exerts its effects, and of how
to control the application of TMS to exert the desired effects. Although most clinical
trials have focused on the treatment of major depression, increasing attention has been
paid to schizophrenia and anxiety disorders. Many of these trials have supported a
significant effect of TMS, but in some studies the effect is small and short lived.
Current challenges in the field include determining how to enhance the efficacy of
TMS in these disorders and how to identify patients for whom TMS may be
efficacious. Key Words: DLPFC, dorsolateral prefrontal cortex; ECT, electroconvul-
sive therapy; FDG, fluorodeoxyglucose; HRSD, Hamilton Rating Scale for Depres-
sion; MT, motor threshold; OCD, obsessive compulsive disorder; PET, positron
emission tomography; PTSD, post traumatic stress disorder; rCBF, regional cerebral
blood flow; SPECT, single photon emission computed tomography; TMS, transcranial
magnetic stimulation.
Soon after transcranial magnetic stimulation (TMS)
was introduced as a noninvasive means of cortical stim-
ulation in 1985, its potential utility as a therapeutic
intervention in psychiatry was explored. Initial studies
used single magnetic pulses administered at low frequen-
cies with large stimulating coils to broad regions of the
cortex. When repetitive TMS stimulators became avail-
able, attention shifted to higher frequencies of stimula-
tion, which appeared more effective in influencing
higher cognitive functions such as language (Claus et al.,
1993; Epstein et al., 1999; Michelucci et al., 1994;
Pascual–Leone et al., 1991). Based on theories regarding
focal brain regions involved in depression, subsequent
trials used the more focal figure-of-eight coil. In distinc-
tion to the development of new psychopharmacologic
agents, exhaustive animal studies on the behavioral ef-
fects of TMS did not precede clinical testing, although in
recent years such animal work has been informative.
Most clinical trials with TMS have involved small num-
bers of patients and have focused on major depression.
The results of these trials, and of work in schizophrenia,
anxiety disorders, and other potential applications are
reviewed. Neuroimaging studies and animal models rel-
evant to the potential mechanisms of action of TMS in
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psychiatric disorders are included whenever available. In
this review we focus exclusively on relevant clinical
studies. Preclinical studies have been reviewed exten-
sively elsewhere (Lisanby and Belmaker, 2000; Post and
Keck, 2001).
CLINICAL TRIAL DESIGN WITH
TRANSCRANIAL MAGNETIC STIMULATION
The conventions in clinical trials on pharmaceutical
agents in the treatment of psychiatric disorders do not
translate perfectly to the study of TMS as a therapeutic
intervention. Special challenges in clinical trial design
with TMS include blinding, standardization of dosage,
selection of a clinically appropriate target for stimula-
tion, and navigation to that target.
There is currently no consensus on the ideal “placebo”
condition for TMS to blind patients and investigators.
Initial studies with TMS were open, uncontrolled inves-
tigations. Both patients and investigators knew that the
patient was receiving a cutting-edge technology in which
both parties placed a good deal of faith. The administra-
tion of TMS involves intense and frequent contact be-
tween doctor and patient of a sort that is not typical in
conventional office-based psychiatric practice. To con-
trol for these ancillary aspects of the intervention, vari-
ous “sham” TMS conditions have been adopted.
Sham TMS is typically applied by tilting the coil off
the head such that the magnetic field grazes the scalp,
stimulating the scalp muscles and producing a clicking
noise, but not affecting the brain (Fig. 1). However, there
is evidence that some types of sham manipulations used
in clinical trials actually do exert some effects on the
brain (Lisanby et al., 2001a; Loo et al., 2000). Even if a
form of coil-tilt sham that does not exert measurable
brain effects is used, studies rarely report data on the
integrity of the blind on the part of the patients and raters.
It is reasonable to assume that crossover trials with
coil-tilt sham conditions are likely to be unblinded be-
cause active and sham TMS do not feel the same. In our
work using a crossover design with a coil-tilt sham,
patients could readily discriminate between active and
sham TMS (Boylan et al., 2001). Although coil-tilt
shams may be of some utility in blinding patients in
parallel design studies, they nevertheless do not blind the
investigator.
At least two manufacturers now offer sham coils that
look the same and are held the same as active coils, but
use mu-metal to shield the patient from the magnetic
field. This strategy may become important for blinding
the physician administering TMS, but their utility in
blinding patients remains to be determined.
The difficulty in blinding TMS makes the comparison
of TMS with a gold standard treatment (e.g., psychop-
harmacology or electroconvulsive therapy [ECT]) com-
plex. In the case of pharmacologic agents, it would be
possible to use a “double-dummy” design in which some
patients would receive sham TMS plus active medica-
tion, whereas other patients would receive active TMS
and a placebo pill. To date, no published studies have
used this design, yet comparison of TMS with a gold
standard is a necessary step in the evaluation of the
potential clinical role of this intervention. Unfortunately,
a double-dummy design is not possible with ECT. This
represents a serious design limitation in studies that
randomize patients to receive either ECT or TMS.
FIG. 1. Typical orientations for active and sham transcranial magnetic stimulation (TMS) with a figure-of-eight coil. (A) Active TMS is applied with
the figure-of-eight coil tangential to the scalp. (B) Sham TMS with two wings of the figure-of-eight coil touching the scalp, but the intersection of
the coil windings is tilted off the head by 45 deg. This orientation can still produce motor movement when positioned over the motor cortex with some
manufacturers’ coils. (C) Sham TMS with 1 wing of the figure-of-eight coil touching the scalp, and the intersection of the coil windings tilted off
the head by 90 deg. This orientation does not elicit motor movement when positioned over the motor cortex. It is also easier to distinguish from active
TMS as a result of less intensive contraction of scalp muscles.
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An additional challenge in the design of clinical trials
with TMS has to do with standardization of the dosage.
Just as it is critical to control the dosage of medication
administered during drug trials, it is likewise essential to
control the amount of TMS administered and the location
of the brain region stimulated. Unfortunately, these fac-
tors are controlled for poorly by the current standard
methods. The convention is to administer an intensity
that is set relative to the threshold for eliciting a motor
evoked potential (or in some centers, a visible twitch) in
a distal hand muscle. Although setting intensity relative
to this measurable peripheral effect may be appropriate
for motor stimulation, its relevance to thresholds for
stimulation of other areas is unknown. Reliable methods
for determining functional thresholds for other brain
regions have yet to be determined. Imaging the effects of
TMS in targeted regions (Bohning et al., 1999), and then
linking those effects to a more readily available measure
would be one such strategy. Because it is known that the
strength of the magnetic field is determined by the
distance from the coil to the target brain structure, one
approach would be to set intensity based on coil-to-brain
distance as measured on a structural MRI (Kozel et al.,
2000; McConnell et al., 2001). Although magnetic field
strength in target regions can be computed, the induced
electrical field and current density depend on other fac-
tors, some of which cannot be measured noninvasively
(Lisanby et al., 1998). Nevertheless, use of structural
imaging and magnetic field modeling could only serve to
improve the current practice.
Beyond issues of standardization of dosage, other
factors that have been controlled poorly in clinical stud-
ies with TMS include the selection and localization of
the particular cortical target to stimulate. Depression has
been linked to abnormalities in a network of brain re-
gions, many of which are not easily accessible to the
TMS coil (Mayberg, 1997; Soares and Mann, 1997). The
dorsolateral prefrontal cortex (DLPFC) figures promi-
nently in depression models, but it also plays other roles
in cognitive operations and is implicated in schizophre-
nia. The orbital prefrontal cortex and regions of the
anterior cingulate have been recognized increasingly to
play key roles in depression circuitry, but these are not
directly accessible to the TMS coil. After the target
region is selected, it is difficult to predict how a given
frequency of TMS applied to that target will affect
activity at the site of stimulation and in connected re-
gions (Kimbrell et al., 1999). It is quite possible that the
effect of TMS on the circuit may depend in part on the
baseline activity in the region stimulated. Most psychi-
atric disorders are heterogeneous in their presentation
and in their patterns of brain activity. Studies of the
effects of TMS on functional connectivity in psychiatric
disorders (reviewed later) are important in the selection
of appropriate patients and appropriate stimulation par-
adigms to achieve the desired effects.
When the target region has been selected, navigating
the coil to the scalp position nearest to that region is not
a trivial problem. Most clinical trials in depression have
targeted the DLPFC by moving the coil 5 cm anterior to
the optimal site for stimulation of a distal hand muscle.
Studies have shown this method to introduce a great deal
of variability in ultimate coil position (Kozel et al.,
2000). Frameless stereotaxic systems have been devel-
oped to guide the coil to regions selected on the individ-
ual’s MRI, but such technology is expensive and of
limited availability (Herwig et al., 2001; Krings et al.,
1997; Krings, 1997; Paus, 1999; Paus and Wolforth,
1998). Herwig et al. (2001) compared the standard
means of coil positioning with frameless stereotaxy and
demonstrated that in only 7 of 22 subjects was the
DLPFC targeted correctly with the standard means. In
the remaining 15 subjects, the center of the coil was
located more dorsally, over the premotor cortex (Herwig
et al., 2001). When frameless stereotaxic positioning is
not available, a better compromise may be to make use of
scalp landmarks and the International 10-20 EEG posi-
tioning system, which takes into account variation in
head size and for which studies have documented rea-
sonable correspondence with underlying cortical struc-
tures (Homan et al., 1987).
MAJOR DEPRESSION
Trials with Single-Pulse and Low-Frequency
Transcranial Magnetic Stimulation
The earliest studies of TMS in the treatment of major
depression used single-pulse TMS (0.3 Hz), usually
administered with a large, round coil centered on the
vertex (Geller et al., 1997; Höflich et al., 1993; Kolbin-
ger et al., 1995; Menkes et al., 1999). In this position, the
round coil stimulates broad regions of the bilateral fron-
tal and parietal cortices. These early trials characteristi-
cally reported significant antidepressant effects of TMS.
One of these studies was sham controlled (Kolbinger et
al., 1995). Despite the promising results, these studies
have not yet been followed up with larger controlled
trials using large coils at slow frequencies. Large coils
induce stronger electrical fields in the brain than small
coils because the strength of the induced electrical field
is proportional to the ratio between the size of the coil
and the size of the brain (Weissman et al., 1992). Be-
cause the coil-to-brain ratio achieved in these studies
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matches more closely that achieved in most animal
studies of TMS showing action consistent with antide-
pressant activity (Belmaker and Grisaru, 1998; Belmaker
et al., 1997, 2000; Fleischmann et al., 1995; Lisanby and
Belmaker, 2000), and because single-pulse TMS has a
much better safety profile than repetitive TMS (Wasser-
mann, 1998), it may be worth revisiting the utility of
large coils and low frequencies. Typical coil designs for
human and animal trials are illustrated in Fig. 2.
Using a slightly higher frequency (1 Hz) and a slightly
smaller round coil positioned on the right prefrontal
cortex, Feinsod et al. (1998) reported improvement in 7
of 14 depressed patients. The same group went on to
perform a sham-controlled trial of 1-Hz TMS adminis-
tered with a round coil positioned on the right prefrontal
cortex for 10 daily sessions (Klein et al., 1999). In what
remains the largest single-site TMS depression study to
date, Klein et al. (1999) found a response rate of 31%
percent with active TMS and 14% with sham. This
difference was significant and represents one of the
largest effect sizes reported. Like single-pulse TMS, 1
Hz carries a much lower seizure risk than frequencies
more than 1 Hz (Wassermann, 1998). Therefore, the
utility of low-frequency TMS in clinical treatment de-
serves further exploration.
Open Trials of High-Frequency Transcranial
Magnetic Stimulation
Several open studies have offered support for antide-
pressant efficacy of TMS, but the possibility of placebo
response must be kept in mind in interpreting these
results. George et al. (1995) reported that five daily
sessions of TMS delivered to the left DLPFC at 20 Hz,
80% of motor threshold (MT), 2-second trains, 20 trains
per day, reduced depression scores in four of six medi-
cation-resistant depressed patients (George et al., 1995).
The effects of five daily session of TMS delivered to the
left DLPFC at 10 Hz, 110% of MT, 5-second trains, 10
trains per day were reported by Epstein et al. (1998).
Fifty-six percent of patients met response criteria. Ex-
tending the treatment to 10 days and increasing the
number of pulses per day to 2,000 (20 Hz, 80% of MT,
2-second trains, 50 trains per day), Triggs et al. (1999)
reported a 50% response rate in 10 medication-resistant
unipolar depressed patients. Pridmore et al. (1999) ad-
vocated extending the period of treatment to 3 or 4
weeks. In their open study of 22 patients with melan-
cholic depression referred for ECT treated with 1,250
pulses per day (10 Hz, 90 to 100% of MT, 5-second
trains, 25 trains per day), TMS to the left DLPFC
FIG. 2. Typical coil configurations used in human and animal trials. (Top row) Round coils (left, animal/pediatric; right, human). (Bottom row)
Figure-of-eight coils (left, rodent; middle, nonhuman primate/pediatric; right, human).
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resulted in remission in 88% of patients. Although pla-
cebo response may have contributed to this effect, it may
be that longer treatment is more effective or that patients
with melancholic subtype are more responsive to TMS.
Of note, the psychomotor symptoms of melancholia
predict response to ECT (Hickie et al., 1990). Others
have also observed normalization of the dexamethasone
suppression test, a marker for endogenous depression,
after TMS (Pridmore, 1999; Reid and Pridmore, 1999).
Another strategy that has been explored to enhance
efficacy is to combine high-frequency TMS to the left
DLPFC with low frequency to the right DLPFC. In a
small open study of 10 medication-resistant patients,
Cohen et al. (personal communication, May 2002) found
that up to 2 weeks of treatment with 20-Hz TMS to the
left DLPFC followed by 1-Hz TMS to the right DLPFC
was well tolerated and resulted in a 40% response rate. It
is possible that the response rate may have been even
better had the treatment period been extended to 3 or 4
weeks.
A recent meta-analysis of the open trials of TMS in
depression found an effect size of 1.45 (Burt et al., 2002).
Although significant, the degree of clinical improvement
was modest, with an average 37.0% (standard deviation,
29.2%) improvement in depression ratings.
Transcranial Magnetic Stimulation versus
Electroconvulsive Therapy
In many centers, the patients who volunteer for TMS
are seeking an alternative to ECT. Although ECT is
extremely effective in treating severe depression, its
cognitive side effects limit its use. Three groups have
performed direct comparisons between ECT and TMS.
Grunhaus et al. (2000) randomized 40 patients to
receive ECT or up to 40 weeks of high-frequency TMS
to the left DLPFC. Overall, patients responded better to
ECT. This advantage was primarily the result of the
subgroup with psychotic depression, in which ECT was
clearly superior. For nonpsychotic patients there was no
difference between ECT and TMS. Unfortunately the
rater in this study was not blinded. In a study using
blinded raters, Pridmore et al. (2000) randomized 32
patients to receive TMS or right unilateral ECT. The
number of treatments was not predetermined but was
selected by the patient’s treating psychiatrist. The re-
sponse rate based on change in the Hamilton Rating
Scale for Depression (HRSD) score was identical in both
groups (66%), but ECT was superior in terms of self-
report measures. The same group compared the efficacy
of six ECT treatments with two ECT treatments in
combination with eight TMS sessions (Pridmore, 2000).
Although they found no difference between ECT and
ECT  TMS, it is important to note that administration
of only six unilateral ECT treatments is not optimal
treatment. Using bilateral ECT, Janicak et al. (2002)
completed a similar randomized study involving 25 pa-
tients, and again failed to find a difference in efficacy
between ECT and TMS.
A recent meta-analysis of these comparisons failed to
find a significant difference in efficacy between the
groups (Burt et al., 2002), however none of these studies
can be considered truly blinded. Another limitation is
that the response rate to ECT in these studies was
unusually low. On the other hand, TMS could still
become a useful treatment even if it falls short of match-
ing the efficacy of ECT, considering its much more
benign side effect profile.
Blinded Trials of Transcranial Magnetic
Stimulation
A series of sham-controlled trials have examined the
efficacy of TMS in depression. The first controlled trial
(Pascual–Leone et al., 1996) is still the only published
trial to have compared the antidepressant efficacy of
high-frequency TMS applied to different cortical re-
gions. It bears remembering that the optimal stimulation
site for antidepressant effects may not have been identi-
fied yet. Pascual–Leone et al. (1996) treated 17 medica-
tion-resistant psychotic, depressed patients with 1 week
of daily TMS (10 Hz, 90% MT, 10-second trains, 20
trains per day) or sham TMS to each of three different
locations (vertex, left or right DLPFC). At 100% of MT,
the longest train recommended by safety guidelines is 5
seconds, so the 10-second trains administered during this
study represent quite robust stimulation. Only the active
stimulation of the left DLPFC resulted in improvement.
Eleven of 17 patients were improved significantly. Al-
though their improvements diminished within 2 weeks,
such an impressive and rapid clinical response in this
severely ill group of patients is remarkable. As an intra-
subject crossover trial, it is quite likely that the patients
became unblinded to the treatment condition. Indeed,
subsequent studies have failed to find benefits of TMS in
psychotic depression (Grunhaus et al., 2000).
Also using a sham-controlled crossover design,
George et al. (1996) found a significant effect of 2 weeks
of active 20-Hz TMS to the left DLPFC in 12 depressed
patients. Although significant, the effect size was small
in comparison with that of the Pascual–Leone (1996)
trial (average 5-point drop in depression scores with
active and 3-point increase with sham). Again, the pos-
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sibility of unblinding resulting from the crossover design
must be considered.
Results in studies using a parallel group design have
been mixed. Loo et al. (1999) failed to find a difference
between 2 weeks of sham and active TMS (10 Hz, 110%
MT, 5 seconds, 30 trains) in 18 medication-resistant
depressed patients. Given that both groups improved, the
question has been raised regarding whether the sham
used (45-deg coil tilt) may have been somewhat active
(Lisanby et al., 2001a; Loo et al., 2000). Berman et al.
(2000) was able to detect a difference between sham and
active TMS (20 Hz, 80% MT, 2 seconds, 20 trains) in 20
medication-resistant depressed patients. Although they
also used a 45-deg coil tilt, the coil they used was
enclosed in a thick casing (used for water cooling of the
coil, which elevates the coil windings approximately 0.5
cm off the scalp). The clinical response was significant
but modest in magnitude (14-point drop in HRSD score
with active and 0-point drop in sham).
Two parallel group studies of TMS in the elderly have
been negative. Manes et al. (2001) found response rates
of 30% with sham and 30% with active TMS (20 Hz,
80% MT, five daily treatments) in 20 elderly, depressed
patients (Manes and Crespo–Facorro, 1999). Using a
higher intensity of 100% of MT and 2 weeks of treat-
ment, Mosimann et al. (2000) failed to find a difference
between active and sham TMS in 25 elderly patients.
These controlled observations confirm open data from
Figiel et al. (1998), who reported that only 23% of
patients older than 65 years responded to TMS, com-
pared with 56% of younger patients. It has been sug-
gested that lower response rates in the elderly may result
from inadequate dosing (Kozel et al., 2000). Alterna-
tively, cerebral atrophy would increase the distance from
the coil to the brain, thereby decreasing the strength of
the induced electrical current. Dosing relative to MT may
not compensate adequately for this increase in distance
because cortical atrophy is not necessarily symmetric in
all brain regions.
Several groups have examined the utility of TMS as an
add-on to pharmacotherapy in the treatment of depres-
sion. Although an open study by Conca et al. (1996)
suggested that single-pulse TMS to multiple scalp loca-
tions in addition to various medications was more effec-
tive than medications alone, a sham-controlled trial by
Garcia–Toro et al. (2001) failed to find a benefit with left
DLPFC 20-Hz TMS augmentation of sertraline therapy.
Lisanby et al. (2001d) placed 36 patients on sertraline
and randomized them to receive 10 daily sessions of
sham, 1-Hz TMS to the right DLPFC or 10-Hz TMS to
the left DLPFC (Lisanby et al., 2001d). The therapeutic
results were disappointing, with effect sizes of only 0.24
for 20 Hz and 0.20 for 1-Hz TMS. Patients who were
classified as not medication resistant at baseline showed
substantial improvement regardless of TMS condition,
whereas medication-resistant patients showed little
change. There was an indication that medication-resis-
tant patients showed a small but significant benefit in the
10-Hz TMS left DLPFC condition. In all three of these
studies, antidepressant medications were initiated con-
currently with TMS (Conca et al., 1996; Garcia-Toro et
al., 2001; Lisanby et al., 2001d).
Although there is not convincing evidence that TMS
can speed onset of action, better effects may be seen with
TMS as an add-on to ongoing pharmacotherapy to aug-
ment response. Indeed, most studies of TMS in depres-
sion have allowed patients to remain on stable doses of
antidepressant medications during the TMS trial. Garcia–
Toro et al. (2001) randomized depressed patients on
stable doses of antidepressant medications for 6 weeks to
receive sham or active TMS (20 Hz), and found a modest
clinical benefit to active TMS (drop in depression scores
of 7 points with active and 2 points with sham; response
rates of 25% with active and 5% with sham).
Meta-analysis revealed that across the 23 controlled
comparisons, the combined effect size was 0.62, indicat-
ing a moderate to large effect (Burt et al., 2002). Al-
though this effect size is significant, the magnitude of the
effect in most studies was modest and of doubtful clin-
ical importance. The average percent improvement with
active TMS was 28.94% (standard deviation, 23.19%)
and with sham was 6.63% (standard deviation, 25.56%).
Relatively few patients met standard criteria for response
(e.g., 50% reduction in HRSD scores) or remission (e.g.,
final HRSD score  8 points). The presence or absence
of concomitant antidepressant medications did not alter
the effect size.
Meta-analysis failed to find a significant difference
between effect sizes in low-frequency and high-fre-
quency studies (Burt et al., 2002). However, some head-
to-head comparisons suggest low frequency may actually
fare better than high frequency (George et al., 2000;
Kimbrell et al., 1999; Padberg et al., 1999). Kimbrell et
al. (1999) reported a trend toward better improvement
after 2 weeks of 1-Hz TMS compared with 20 Hz to the
left DLPFC (drop of 6 points in HRSD score with 1 Hz,
and increase of 1.2 points with 20 Hz) in a crossover
design. A negative correlation was found between clin-
ical response to 1 Hz and 20 Hz, and there were sugges-
tions that baseline metabolic activity in the DLPFC
correlated with response. George et al. (2000) random-
ized patients to active TMS at 5 Hz, 20 Hz, or sham to
the left DLPFC. Response rates were 60% with 5 Hz,
30% with 20 Hz, and 0% with sham. If lower frequencies
349TMS IN PSYCHIATRY
J Clin Neurophysiol, Vol. 19, No. 4, 2002
are indeed as effective (or even more effective) than
higher frequencies, this would have significant safety
implications because lower frequencies carry less risk of
seizure.
Magnetic Seizure Therapy
All of the previously mentioned studies involved the
use of levels of TMS that were below the threshold for
inducing seizure. Subconvulsive TMS is administered
without the need for anesthesia and is generally per-
formed as an ambulatory procedure. In parallel with
work on subconvulsive forms of TMS, there has been
some interest in exploring the uses of convulsive levels
of TMS in the treatment of depression. In 1994, Sackeim
(1994) postulated that magnetically induced seizures
might have some advantages over conventional ECT.
Conventional ECT is highly effective, but it carries a
substantial risk of memory loss and other side effects.
Electroconvulsive therapy research during the past few
decades has indicated that the efficacy and side effects of
ECT depend in part on the site of seizure onset and
patterns of seizure spread (Lisanby et al., 2000; Luber et
al., 2000; Sackeim et al., 1993, 2000a, b). There is little
hope of controlling these factors with conventional ECT
because the application of electricity through the scalp is
inherently imprecise. The scalp and skull act as effective
resistors to the flow of electricity, causing the stimulation
to diffuse (Sackeim et al., 1994). Transcranial magnetic
stimulation, on the other hand, passes through tissue
without impedance, permitting a more localized stimu-
lation. Transcranial magnetic stimulation presents the
possibility of using noninvasive magnetic fields to in-
duce focal seizures, thereby sparing other regions of the
brain involved in amnestic side effects.
This method was first developed and tested in rhesus
monkeys (Lisanby et al., 2001c), and was recently sub-
jected to the first clinical trials. The procedure is per-
formed under anesthesia of the sort used in conventional
ECT. The first open case report of magnetic seizure
therapy in the treatment of major depression documented
a 40% improvement in depression ratings after four
treatments (Lisanby et al., 2001e). The treatments were
well tolerated with minimal side effects. Subsequently,
Lisanby et al. (2001b) performed a controlled clinical
trial of 10 patients with major depression. Each patient
received a course of convulsive therapy in which two of
the first four treatments were induced magnetically
(counterbalanced order), and the remaining were induced
electrically (Lisanby et al., 2001b). Acute cognitive side
effects were measured with blinded neuropsychological
batteries, and subjective side effects were compared.
Treatments were well tolerated with no adverse events.
Magnetic seizure therapy had fewer subjective side ef-
fects and patients recovered orientation more quickly
than with ECT. Magnetic seizure therapy was superior to
ECT on some but not all cognitive measures. This study
demonstrated that magnetic seizure therapy in patients
with depression is feasible, and appears to be a well-
tolerated method for performing convulsive therapy.
More work is needed to establish whether magnetic
seizure therapy will have comparable antidepressant ef-
ficacy with ECT.
Relevant Imaging Studies
The mood-elevating effects of TMS seen in some
studies may reflect changes in activity in regions remote
from the site of direct stimulation. Szuba et al. (2001)
found that a single session of TMS to the left DLPFC in
depressed patients increased thyroid-stimulating hor-
mone in peripheral blood, suggesting an effect on the
hypothalamus–pituitary–thyroid axis. Similar findings
were reported by George et al. (1996) in normal volun-
teers. It is not clear whether this thyroid effect is related
to the mood effects, because the two were uncorrelated in
both studies. Functional neuroimaging using oxygen
(O15) or fluorodeoxyglucose (FDG) positron emission
tomography (PET), single photon emission computerized
tomography (SPECT), or functional MRI provides a
more precise method of mapping the effect of TMS on
depression circuitry.
Activation of brain regions removed from the stimu-
lation site can provide information on the functional
connectivity of cortical and subcortical structures rele-
vant for understanding the neural circuits involved in
depression (Fox et al., 1997; Siebner et al., 2000, 2001).
For example, proximal brain activation effects obtained
during TMS are generally thought to reflect local cortical
excitability, whereas distal effects may reflect connec-
tivity to the stimulated region. Imaging at multiple time
points can also provide information on the time course of
activation of various brain regions. Like antidepressant
medications, TMS probably produces dynamic changes
(both acute and chronic), the full extent of which cannot
be captured by imaging at only a few time points.
Although it is not clear to what extent findings ob-
tained with normal subjects can be extrapolated to de-
pressed patients, imaging studies in normal control sub-
jects can shed light on the underlying connectivity of the
stimulated region. One, 2, and 5-Hz TMS over motor
cortex concurrent with neuroimaging has been shown to
produce regional cerebral blood flow (rCBF), regional
cerebral glucose metabolic rate, and blood oxygenation
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level-dependent increases at the stimulation site in nor-
mal subjects (Bohning et al., 1999; Fox et al., 1997;
Siebner et al., 2000, 2001), yet different patterns are
observed in normal subjects after left prefrontal TMS
(George et al., 1999; Nahas et al., 2001a, b). George et al.
(1999) performed a SPECT study of eight subjects be-
fore DLPFC stimulation, during 10 to 20 seconds of a
2-minute train of 10-Hz TMS, and during a 2-minute
train of TMS after a prior 18 minutes of TMS. Although
no increase in perfusion was produced at the coil site,
increases were observed in the orbitofrontal cortex and
the hypothalamus at both 2 minutes and 20 minutes (20
 2), and in the thalamus at 20 minutes. At 20 minutes,
decreases were observed in the right PFC, bilateral an-
terior cingulate, and temporal cortices. The authors sug-
gest that the cingulate effects may explain the mood-
altering effects of TMS observed in depressed patients.
The only study using functional MRI to measure
cerebral effects of interleaved TMS was performed by
(Nahas et al., 2001). A 1.5-T MRI scanner was used to
image five normal subjects during short trains of 1-Hz
left prefrontal TMS at 80%, 100%, and 120% of MT.
Subjects performed a continuous performance task
throughout scanning that required them to lift their index
finger at the sound of a tone, leading to significant
activation of auditory cortex and right insula. There was
a significant increase in perfusion under the coil at 120%
of MT when compared with rest. Increases were also
observed in the right orbitofrontal cortex at 120% of MT,
and in the prefrontal cortex at both 100% and 120% of
MT. The only significant cingulate effects were left-side
increases, and were observed only when 120% MT was
compared with 80% MT. The task performance may also
have influenced the activations observed.
The first functional imaging study of a depressed
patient undergoing TMS treatment was performed by
George et al. (1995). A baseline FDG PET scan revealed
global hypometabolism that normalized after treatment
of depressive symptoms by 20-Hz TMS (80% of MT). A
further increase in metabolism was observed when FDG
injection occurred during concurrent stimulation. It is
important to recognize that changes observed in activa-
tion patterns may be the result of TMS effects, resolution
of depressive symptoms, or both. Nonetheless it has been
suggested that the antidepressant effect of high-fre-
quency TMS could be the result of activation of such
hypofunctional areas.
Kimbrell et al. (1999) performed a quantified FDG
PET study comparing randomized 20-Hz (80% of
MT), 1-Hz, and sham left DLPFC TMS in 13 unipolar
(medication free) and bipolar (one of four medication
free) depressed patients and found that better antide-
pressant response to 20-Hz TMS was associated with
greater baseline hypometabolism in the bilateral tem-
poral, anterior cingulate, occipital, and cerebellar re-
gions, whereas response to 1-Hz treatment, although
nonsignificant, was associated with global baseline
hypermetabolism. These findings may also be consis-
tent with the hypotheses of Mayberg et al. (1999) that
it is not a specific change in activity in any given
region that mediates resolution of depressive symp-
tomatology, but a reconfiguration of prefrontal and
cingulate interactions. Further studies should be car-
ried out to determine whether pretreatment activation
patterns may predict whether patients would respond
better to high- or low-frequency TMS. Consistent with
this idea, a possibly related phenomenon was observed
in two separate studies performed by the same group
(Speer et al., 2000; Kimbrell et al., 1999). Patients
whose depression improved with 1-Hz TMS tended to
worsen with 20-Hz TMS, and vice versa (r  0.78,
P  0.005 [Speer et al., 2000]; r  0.80, P  0.004
[Kimbrell et al., 1999]). These findings suggest that,
just as some patients respond better to one antidepres-
sant medication than another, so might they respond
better to one frequency of TMS than another.
Seemingly contradictory effects were observed with
low-frequency stimulation in another study, however.
Conca et al. (2002) imaged four drug-resistant (medicat-
ed) depressed patients with SPECT and FDG PET before
and one day after 10 sessions of alternating right- and
left-hemisphere single-pulse TMS. In contrast to the
baseline hypermetabolism associated with response to
low-frequency TMS observed by Kimbrell et al. (1999),
in this study a moderate hypofrontality (medial frontal
gyrus) was observed in the baseline FDG PET images
that disappeared with remission of symptoms. Glucose
uptake and rCBF also increased significantly in bilateral
prefrontal regions of interest corresponding to the coil
location, and decreased in left orbitofrontal regions.
These findings are more difficult to interpret than those
of Kimbrell et al. (1999), however, given the small
sample size, concurrent antidepressant medications, and
particular stimulation parameters used.
Teneback et al. (1999) also observed a correlation
between response to TMS and brain activity patterns. In
this study, 22 largely medication-resistant unmedicated
unipolar or bipolar depressed patients received either 2
weeks of active (n  13) 20-Hz (100% of MT), 5-Hz
(100% of MT), or sham (n  9) left prefrontal stimula-
tion and underwent SPECT scanning 3 days before and 3
to 4 days after treatment. At baseline, depression severity
was correlated inversely with activity in the left prefron-
tal cortex and the bilateral medial temporal lobe and
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caudate, which normalized in TMS responders after
treatment. Yet when compared with nonresponders, re-
sponders exhibited increased inferior frontal activity at
baseline and further increases with treatment, and also
showed decreased activity in the right medial temporal
lobe with treatment. Regional CBF also changed in
limbic regions as a function of mood improvement in
sham responders.
High-frequency (1-Hz) TMS is thought to induce
cerebral excitation whereas low-frequency (1 Hz)
TMS is thought to induce cerebral depression, yet few
neuroimaging studies of depressed patients have tested
this hypothesis by directly comparing high- and low-
frequency TMS. In a study by Speer et al. (2000), 10
medication-free depressed patients received 2 weeks of
either 20-Hz (100% of MT), 1-Hz (100% of MT), or
sham TMS over the DLPFC in a crossover design (those
receiving sham first next received 20 Hz, whereas those
who received active TMS first were crossed over to the
other frequency) at 100% of MT. Quantitative O15 PET
images were acquired at baseline and 72 hours after
completion of the last TMS treatment at each frequency.
As in normal subjects, 20-Hz TMS produced wide-
spread, mainly left-side increases in rCBF in the prefron-
tal and cingulate cortices. Increases also occurred in the
left amygdala, and bilateral insula, basal ganglia, uncus,
hippocampus, parahippocampus, thalamus, and cerebel-
lum. One-Hertz TMS produced only decreases that were
much smaller in spatial extent in the right prefrontal
cortex, left medial temporal cortex, basal ganglia, and
amygdala.
Speer et al. (2000) suggest that the differential effects
of high- versus low-frequency TMS may be analogous to
the effects of stimulation on cortical, hippocampal, and
cerebellar slice preparations, in which high-frequency
stimulation leads to long-term potentiation, whereas low-
frequency stimulation produces long-term depression
(Christie and Abraham, 1994; Malenka, 1994; O’Dell
and Kandel, 1994).
Variable results have also been obtained in studies that
examined high-frequency stimulation alone. Nahas et al.
(2001) measured rCBF with SPECT in 23 unipolar or
bipolar depressed patients (three of whom were on con-
comitant mood stabilizers) during sham or left DLPFC
TMS (100% of MT) at 20 Hz or 5 Hz for 10 days.
Scanning occurred before TMS treatment and again
during the fifth treatment session. Increases in rCBF
associated with active TMS were observed at the stimu-
lation site. The right medial frontal lobe increases, and
the anterior cingulate and anterior temporal pole de-
creases, were similar to the results obtained by George et
al. (1999) in normal subjects. Twenty-Hertz and 5-Hz
TMS also produced differential effects, although with
their method of analysis, the authors could not determine
how they differed.
Zheng et al. (2000) measured rCBF with SPECT
following 10-Hz left DLPFC TMS (110% of MT) in five
drug-resistant depressed patients. Scans acquired 48
hours after treatment were compared with baseline and,
as in other studies (e.g., Speer et al., 2000), an increase
was observed in the left anterior cingulate. Although
visual inspection of individual patients’ SPECT images
showed both increased and decreased rCBF in different
regions, no significant change in either direction was
observed in any other region when analyzed across
subjects, most likely because of the small sample size
and high individual variability in response.
Catafau et al. (2001) examined seven medication-
resistant medicated depressed patients (two of whom
were also resistant to ECT) with SPECT at baseline,
during the first TMS session, and 1 week after 10 daily
20-Hz left DLPFC TMS (90% of MT) sessions. Sig-
nificant increases in rCBF were observed in a left
prefrontal region of interest after the final TMS treat-
ment, but no significant changes were observed after
the first treatment. No other regions demonstrated
significant changes from baseline, again possibly be-
cause of the small sample size and high individual
variability in response.
In summary, the many variables that must be ac-
counted for in interpreting the cerebral activation effects
of TMS on depressed patients make it difficult to inte-
grate the findings across studies. Larger and better con-
trolled studies are needed that control for intersubject
variability in a depressive state, response to TMS, and
concomitant medications, all of which may affect pre-
and posttreatment perfusion patterns. The cerebral acti-
vation patterns produced by stimulation have also been
shown to vary with coil placement (Paus et al., 1997,
1998), intensity of stimulation (Bohning et al., 1999;
Nahas et al., 2001), frequency (Nahas et al., 2001), and
number of pulse trains administered (Paus et al., 1998).
In addition, the number of treatments before imaging,
time between imaging and TMS sessions, and whether
stimulation was performed before or during neuroimag-
ing may also affect results.
More work is needed to resolve the apparent para-
doxes in the TMS neuroimaging literature. Nonetheless,
the regional brain activity changes produced by TMS
may provide important information regarding the under-
lying neuronal circuitry responsible for mood regulation
and mediation of antidepressant response.
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MANIA
Compared with depression, relatively few studies have
examined systematically the clinical effects of TMS in
mania. Grisaru et al. (1998b) randomized 16 manic
patients to receive high-frequency TMS to the left or
right DLPFC with a round coil for 2 weeks. Manic
symptoms improved significantly only in the right TMS
group. This study suggested that the laterality of effects
in mania with high frequency may be opposite to those in
depression. However, more controlled trials in both dis-
orders comparing right- with left-side stimulation would
be needed to confirm this theory. There was some con-
cern that the differential effects between right and left
TMS may have been complicated by the fact that med-
ications were initiated soon before the trial began. As
such, a difference between the two groups could indicate
that left-sided stimulation impeded the action of the
medications. A sham-controlled trial may help to clarify
this point.
The same group has examined the effects of TMS in
an animal model of mania: the amphetamine hyperactiv-
ity model (Shaldivin et al., 2001). Daily TMS treatments
in rats exerted behavioral effects similar to those seen
with lithium, but twice-daily treatments produced the
opposite effects, suggesting dose dependency in the ac-
tion of TMS. Dosage effects may at least partially ex-
plain the failure of Clark et al. (2000) to find evidence of
activity of a single right 20-Hz TMS session on an
amphetamine model of mania in humans. In summary,
the effects of TMS in mania are unclear, but further work
is warranted.
SCHIZOPHRENIA
Although most of the clinical work to date with TMS
has focused on depression, several of the earliest studies
of TMS in psychiatric populations included schizo-
phrenic patients. These studies used single-pulse TMS
administered with a large round coil to the vertex,
thereby stimulating broad regions of bilateral prefrontal
and parietal cortices. Geller et al. (1997) reported that 6
of 10 medicated chronic schizophrenic patients showed
some transient improvement after a single session of
single-pulse TMS in an open study. Using 2 weeks of
1-Hz TMS with a somewhat smaller round coil posi-
tioned on the right prefrontal cortex, Feinsod et al.
(1998) reported that 7 of 10 schizophrenic patients im-
proved moderately or markedly, and psychosis ratings
dropped significantly. However, when the same group
followed up their findings with a sham-controlled trial in
35 schizophrenic patients, TMS did not differ from
sham.
Hoffman et al. (1999, 2000) had better success with
1-Hz TMS in schizophrenia when the coil was posi-
tioned over the left temporoparietal cortex—a region
that has shown selective activation during auditory
hallucinations (Silbersweig et al., 1995). This trial was
based on the hypothesis that low-frequency TMS may
dampen excitability in the region implicated in this
specific symptom. In an initial crossover study of
three patients, significant reductions in hallucinations
were noted with 4 days of active TMS compared with
sham (Hoffman et al., 1999). Two patients experi-
enced near-total cessation of hallucinations for at least
2 weeks. Of note, all three patients correctly identified
which condition was active—a common occurrence in
crossover studies with TMS. The same group also
conducted a larger crossover trial with 12 patients
(Hoffman et al., 2000). Again, active TMS reduced
hallucinations significantly compared with sham. The
effect was less marked in patients on concomitant
anticonvulsant medications. However, it is not known
whether these patients differed in other ways from
those not on these medications. Other positive and
negative symptoms did not change with treatment. It
will be critical to determine whether other groups can
replicate this finding using a parallel group design to
rule out definitively placebo effects.
Other groups have examined the effects of high-fre-
quency TMS applied to the prefrontal cortex on the
theory that high-frequency TMS may be useful in revers-
ing the hypofrontality observed in schizophrenia. Cohen
et al. (1999) reported an open study of six patients who
received 20-Hz TMS to the midline prefrontal cortex for
at least 2 weeks. They observed a significant reduction in
negative symptoms, but other symptoms and tests of
neuropsychological function were essentially unchanged.
Nahas et al. (1999) administered a single session of
20-Hz TMS to the left DLPFC in 15 patients in a
sham-controlled crossover trial. Improvement was noted
in negative symptoms the day after treatment. Continu-
ing the treatment for 2 weeks, another group reported
that active TMS decreased psychotic symptoms signifi-
cantly in a crossover study of 12 patients (Rollnik et al.,
2000). That study did not specify whether the improve-
ment was in positive or negative symptoms. Interest-
ingly, concomitant depressive symptoms did not im-
prove. A parallel design study of high-frequency TMS to
the DLPFC in schizophrenia would be important to
follow up on these promising results.
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ANXIETY DISORDERS
Post Traumatic Stress Disorder
Limited open studies have been conducted on post
traumatic stress disorder (PTSD). One session of single-
pulse TMS at 100% of stimulator output was applied to
10 PTSD patients (Grisaru et al., 1998a). Each patient
received 15 stimuli to the vertex with a round coil for 15
minutes. A significant improvement was found 24 hours
after treatment, but symptoms returned to baseline by 7
days.
McCann et al. (1998) treated two women with
PTSD openly with 1-Hz TMS to the right frontal
cortex at 80% of MT, with a figure-of-eight coil. Post
traumatic stress disorder symptoms improved during
the final week in one subject and during weeks 2, 3,
and 5 in the other subject. Scores returned to baseline
after the conclusion of treatment. Both patients had
prefrontal hypermetabolism on PET that reversed with
treatment, most markedly in the right prefrontal cor-
tex. These PET data are interesting in light of a study
by Rauch et al. (1996), who reported increased blood
flow to right-side limbic, paralimbic, visual, and fron-
tal areas in patients with PTSD. More recent func-
tional neuroimaging studies have found more bilateral
blood flow decreases in the medial frontal (anterior
cingulate) regions and increases in the orbital frontal
cortex during symptom provocation paradigms in
PTSD patients compared with control subjects (Brem-
ner et al., 1999a, b; Shin et al., 1999). Two of these
studies have also shown a decrease in left inferior
frontal cortex in PTSD patients (Rauch et al., 1996;
Shin et al., 1999).
In a study of 12 patients who had comorbid depression
and PTSD, Rosenberg (personal communication, May
2001), found that 75% of patients had at least a 50%
decrease in HRSD score, but no decrease in PTSD
symptomatology, after 10 days of either 1-Hz or 5-Hz
TMS at 90% of MT to the left DLPFC. At the 2-month
follow up, the antidepressant effects were maintained in
half the patients. Although PTSD is often treated with
antidepressant medications (Pearlstein, 2000), this study
suggests the independence of the neural substrates of
these illnesses.
These preliminary studies do not allow us to conclude
that TMS is an effective treatment for PTSD. However,
these results, and the demonstrated effect that TMS can
have on the hypothalamus–pituitary–adrenal axis (Evers
et al., 2001b; Post and Keck, 2001), warrant further
sham-controlled trials.
Obsessive Compulsive Disorder
In the first study on the effects of TMS on obsessive
compulsive disorder (OCD) symptoms, 12 patients were
treated with 20-Hz stimulation at 80% of MT for 20
minutes (2 seconds on/58 seconds off) (Greenberg et al.,
1997). Transcranial magnetic stimulation was delivered
on three separate days to the left prefrontal cortex, right
prefrontal cortex, and midline occipital cortex using a
figure-of-eight coil. While receiving stimulation to the
right or left prefrontal (but not occipital cortex) compul-
sions were decreased significantly. The decrease in com-
pulsions was greater for right-side stimulation than left,
and the effect persisted for 8 hours. After receiving
stimulation to the right prefrontal cortex, participants
also had improved mood that lasted for at least 30
minutes. There were no changes in obsessions and no
significant differences in compulsions from baseline af-
ter left prefrontal or midline occipital stimulation.
The effect of a longer treatment course in OCD was
explored by Sachdev et al. (2001). Ten daily treatments
with 30 trains of 10-Hz TMS (5 seconds on/25 seconds
off) at 110% of MT were given to 12 treatment-resistant
OCD patients to either the left or right prefrontal cortex,
with a figure-of-eight coil. There was no difference
between the two sites of stimulation. Both groups dem-
onstrated a reduction in obsessions and compulsions as
long as 1 month after treatment. Thirty-three percent of
the subjects (n  4) had a clinically significant improve-
ment in their OCD symptoms.
Extending treatment to 6 weeks, Alonso et al. (2001)
performed a double-blind, placebo-controlled trail in
which patients received either right prefrontal active or
sham 1-Hz TMS. Stimulation was delivered three times
a week for 6 weeks using a round coil at 110% of MT.
During the sham condition the coil was tilted 90-deg and
the intensity was 20% of MT. Neither group showed any
significant improvement in OCD symptoms.
Regions most often implicated in functional neuroim-
aging studies of OCD include the orbital frontal cortex
and the anterior cingulate gyrus (Saxena and Rauch,
2000). Studies on the effects of TMS on OCD have
shown promising results, even though TMS technology
does not allow the direct stimulation of those areas.
Transsynaptic effects on the orbital frontal cortex or the
anterior cingulate gyrus represent a mechanism by which
TMS may influence OCD symptoms (Cummings, 1995;
Paus et al., 2001). Further double-blind, sham-controlled
studies are needed to determine the clinical efficacy of
TMS in OCD.
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COGNITIVE DISORDERS
To date, no studies have examined the use of TMS as
a treatment for patients with cognitive disorders. Differ-
ent frequencies of TMS can both decrease and increase
motor cortical excitability (Chen et al., 1997; Pascual–
Leone et al., 1998; Wu et al., 2000) and exert differential
effects on cerebral activity (Kimbrell et al., 1999; Post et
al., 1999a). This suggests that it has the potential to be
used not only to inhibit brain function, but also to
facilitate it. There are also preliminary animal studies
suggesting that TMS may promote the release of neuro-
protective agents such as brain-derived neurotrophic fac-
tor and secreted amyloid precursor protein (Muller et al.,
2000; Post et al., 1999b). Several controlled studies have
been conducted that illustrate an enhancing effect of
TMS on cognitive function. Single-pulse TMS applied to
Wernicke’s area at 35% and 55% of stimulator output,
500 msec before stimulus presentation facilitated picture
naming (Topper et al., 1998). Stimulation of the parietal
or temporal lobe with single-pulse TMS has been shown
to speed reaction time in a visual object working memory
task (Oliveri et al., 2001). In patients with left temporal
lobe epilepsy, single-pulse TMS delivered to the left
temporal lobe at 120% of MT increased recall for recent
words in a list (Duzel et al., 1996). Boroojerdi et al.
(2001) reported improved performance on an analogic
matching task following 5-Hz TMS at 90% of MT to the
left DLPFC. It has also been reported that 20-Hz TMS
applied to the left prefrontal cortex can speed reaction
time and decrease P300 latency in a visual odd ball task
(Evers et al., 2001a). These studies all produced signif-
icant, but small and short-lived changes in selected
cognitive operations. Although a TMS paradigm may be
identified that could enhance performance on a particular
cognitive task in subjects without cognitive impairment
(as illustrated earlier), it is not clear how the stimulation
would affect other functions subserved by the region
stimulated, nor is it clear how improvement on a partic-
ular task would generalize into clinically meaningful
improvement in a population with cognitive impairment.
More work must be done to elucidate what role, if any,
TMS may play in the treatment of cognitive disorders.
SAFETY OF TMS IN PSYCHIATRIC
DISORDERS
Studies in Normal Volunteers
Until recently, data on the safety of TMS was com-
prised exclusively of studies in normal volunteers, typi-
cally receiving a single TMS session (Jahanshahi et al.,
1997; Pascual–Leone et al., 1993; Wassermann et al.,
1996b) Those studies identified seizure as the most
serious known risk of TMS. These seizures have been
self-limited and have not had adverse sequelae. Risk
factors for seizure include the presence of a structural
brain injury, history of seizure, and family history of
epilepsy. When administered at a sufficiently high fre-
quency or intensity, a long enough duration, or with a
short enough intertrain interval, TMS can induce seizure
independently of these risk factors (Wassermann et al.,
1996a). Guidelines exist to aid the selection of parameter
combinations that are not associated with spread of
excitation within the motor cortex, considered to indicate
that one is near the seizure threshold. However, the
relationship between motor spread and magnetic seizure
threshold has not been examined directly (Wassermann,
1998). Other less serious side effects of TMS include
headache, scalp pain from stimulation of scalp muscles,
and neck pain. Hearing loss is a theoretical risk, and so
earplugs are recommended (Counter, 1994).
Seizure and Spread of Cortical Excitation
There have been two reports of seizure in depressed
patients with stimulation of the prefrontal cortex (Table
1). In both cases, stimulation parameters exceeded the
safety guidelines. In the first case, a 40-year-old woman
with depression receiving a maintenance course of high-
TABLE 1. Cases of seizure and spread of excitation in depressed patients









Female 40 10 10 90% MT Left DLPFC Secondarily generalized seizure
Conca et al., 2000 Female 36 20 10 110% MT Left DLPFC Frontal complex partial seizure
Figiel et al., 1998 Male 66 10 5 110% MT Left DLPFC Brisk proximal right arm
contractions during TMS
Figiel et al., 1998 Female 44 10 5 110% MT Left DLPFC 20 Minutes of motor tics after TMS
DLPFC, dorsolateral prefrontal cortex; MT, motor threshold; TMS, transcranial magnetic stimulation.
355TMS IN PSYCHIATRY
J Clin Neurophysiol, Vol. 19, No. 4, 2002
frequency TMS (10 Hz, 10 seconds, 90% of MT) to the
left DLPFC experienced a secondarily generalized sei-
zure during the first train of stimulation. This was attrib-
uted to initiation of haloperidol (15 mg) and amitripty-
line (20 mg) immediately before that TMS session
without the knowledge of the investigators (Pascual–
Leone, personal communication, June 1996). Impor-
tantly, the MT had not changed, suggesting that MT and
seizure threshold are not necessarily correlated. Of note,
safety guidelines suggest that the longest train at 10 Hz
and 100% of MT should be 5 seconds. The longest safe
train at 90% of MT is not known, but it may be prudent
to adopt the limits for 100% of MT as a conservative
measure, and screen patients carefully for changes in
their medications before each TMS session.
A second seizure in a depressed patient was reported
by Conca et al. (2000) in a 36-year-old woman during
her third train of stimulation at 20 Hz, 10-second dura-
tion, 110% of MT. The longest recommended train at 20
Hz and 110% of MT is 1.6 seconds. After a sensation of
nausea (consistent with an aura), the patient lost con-
sciousness, demonstrated oral automatisms lasting 8 sec-
onds, and experienced postictal amnesia for these events.
There was no motor spread, suggesting this was a frontal
complex partial seizure. Concomitant medications were
trazodone (500 mg/day), citalopram (30 mg/day), loraz-
epam (3 mg/day), and thyroxin (100 g/day). Of note,
the patient had a history of maprotiline-induced general-
ized seizure in the past. It may be wise to consider
patients with a history of seizure, even medication-
induced, at increased risk for TMS-induced seizure.
These two patients also illustrate that extrapolating
above the safety guidelines carries a real risk of seizure.
If guidelines are exceeded, there should be careful jus-
tification for doing so, and patients should be informed
of their increased risk of seizure.
There have been two reports of TMS-induced spread
of excitation (see Table 1). A 66-year-old depressed man
experienced brisk right upper extremity contractions dur-
ing TMS (with stimulation parameters that were within
suggested safety guidelines), which ended when stimu-
lation was stopped (Figiel et al., 1998). Depending on the
latency of the movements relative to each TMS pulse,
this could either represent motor spread or direct stimu-
lation of the motor cortex. Direct motor cortex stimula-
tion could be observed if the intensity was high enough
or if the coil were being held too close to the motor
cortex (such as in the case of difficulty in locating the
optimal site for hand stimulation). Motor spread is a
distinct possibility because the coil used in this study is
a more powerful coil (iron-core coil, Neotonus) than that
used to create the safety guidelines. Because the volume
of tissue stimulated depends on the coil design, it is not
clear that normalizing to the MT is adequate to ensure
that the safety guidelines are directly scalable to all coil
designs and all devices. In another patient in the study by
Figiel et al. (1998) who had a history of motor tics, TMS
triggered 20 minutes of repeated motor tics that subsided
after intravenous lorazepam.
Cognition
Recently, several studies have systematically exam-
ined the neuropsychological effects of repeated sessions
of TMS in clinical psychiatric samples. In an open study
of 10 unipolar depressed patients receiving a robust
amount of high-frequency TMS for 10 days (2000 pulses
per day), Triggs et al. (1999) found no impairment in
performance on a variety of neuropsychological tests. In
fact, some improvements in function were noted, which
may be the result of practice effect or to improved mood.
Likewise, Little et al. (2000) found no cognitive impair-
ments in 10 depressed patients after 2 weeks of high- or
low-frequency TMS to the left DLPFC given at 80% of
MT. Performance on list recall actually improved. The
same group examined the effects of TMS given at 100%
of MT in 18 depressed patients with similar results
(Speer et al., 2001). In another controlled trial, Loo et al.
(2001) examined the effects of as long as 4 weeks of
TMS in 18 depressed patients. They also found trends for
improvements in neuropsychological tests, which were
attributed to practice effects. No evidence of deteriora-
tion in performance was noted, but it is important to
remember that practice effects could mask subtle TMS-
induced cognitive impairment.
Mania
The induction of manic symptoms is a recognized risk
of most antidepressant treatments, including ECT. There
have now been several reports of TMS-induced hypoma-
nia and mania. Nedjat and Folkerts (1999) reported three
cases of TMS (high frequency to the left DLPFC) induc-
ing hypomanic symptoms lasting 24 hours in a study of
50 normal volunteers with no history of psychiatric
illness. There have also been four reported cases of
manic symptoms induced by TMS in unipolar and bipo-
lar patients. George et al. (1995) reported that a unipolar
depressed patient receiving open TMS at 20 Hz to the
left prefrontal cortex developed hypomanic symptoms
after nine daily treatments, which resolved when the
frequency of treatments was reduced to once every other
day. Garcia–Toro (1999) reported that 20 Hz to the left
DLPFC induced manic symptoms reproducibly in a bi-
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polar patient, despite concomitant mood stabilizer med-
ications. Dolberg et al. (2001) reported TMS-induced
mania in two bipolar patients, despite concurrent treat-
ment with therapeutic levels of valproic acid. In the first
case, frank manic symptoms began to manifest during
the third week of daily treatment with high-frequency
TMS to the left DLPFC, and worsened during the fourth
week of treatment. Of note, the patient was withdrawn
from haloperidol immediately before initiating TMS, and
responded promptly to haloperidol once it was restarted
after TMS. In the second case, manic symptoms devel-
oped 5 days after the end of the 4 week course. It is
difficult to know whether this switch was triggered by
the TMS or rather by the natural history of the illness.
Nevertheless, this collection of cases and the evidence in
normal volunteers suggest that manic symptoms are a
potential risk of TMS about which prospective patients
should be informed.
Other Side Effects
Structural MRI performed before and after 2 weeks of
high-frequency TMS to the left DLPFC in depressed
patients failed to show any volumetric changes (Nahas et
al., 2000). Two depressed patients showed mild high-
frequency hearing loss after 6 weeks of exposure to the
TMS auditory artifact, despite the use of earplugs (Loo et
al., 2001). Hearing returned to baseline within a month.
Sedation was noted as a side effect of high-frequency
TMS by Pridmore et al. (1999), and has been seen
occasionally in our experience with some patients actu-
ally falling asleep during high-frequency TMS sessions.
CONCLUSIONS
Transcranial magnetic stimulation remains an investi-
gational intervention that has not yet gained approval by
the Food and Drug Administration for the clinical treat-
ment of any disorder. Despite a growing number of
promising studies on depression, it is still unresolved
whether the magnitude of the effect will turn out to be
clinically important. Effect sizes are consistently higher
in patients referred for ECT, which may indicate some-
thing about proper patient selection to enhance efficacy.
Studies in schizophrenia on both positive and negative
symptoms with TMS administered to the temporoparietal
cortex and DLPFC respectively are encouraging, and
illustrate that TMS may be able to influence symptom
clusters selectively with distinct neural circuitry. A par-
allel group study is now needed to confirm the results to
date in schizophrenia, which have all been crossover
trials.
Considering the relatively primitive methods used to
determine dosage and localization of the TMS coil in
most clinical studies, it is noteworthy that any significant
effects were found. Further functional imaging studies
and animal models are needed to illuminate the effects of
TMS on brain function so that we may then apply these
effects in a selective way to modulate the circuitry
underlying psychiatric disorders. A critical issue is the
selection of TMS dosage. To have adequate power to
detect group differences, clinical trials are limited in the
number of dosages that they can compare head to head.
Dose-finding studies with animals and with functional
neuroimaging could aid selection of the most effective
parameters to test clinically.
Beyond issues of dosage, the reliability of TMS de-
livery in the clinical setting could be improved. Currently
available figure-of-eight coils are flat and couple poorly
to the curved surface of the scalp. Slight changes in the
angle between the plane of the coil and the scalp can
produce large variation in brain effects. Technology
already exists to direct the TMS coil to the scalp position
overlying the target cortical structure, but it has not yet
been adopted widely in the clinical setting. Any method
that could improve the precision and reliability of coil
placement would serve to reduce the noise in the clinical
trials and give the field a clearer picture of the true
clinical potential of TMS.
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